Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 15/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5177529 | 0.92 | CHEK2 (0.71) | CHEK2KDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL1379810 | 0.92 | CHEK2 (0.85) | CHEK2 | |
| SCHEMBL5897709 | 0.85 | CHEK2 (0.73) | CHEK2ALDH1A1KMT2A | |
| SCHEMBL5177601 | 0.83 | CHEK2 (0.66) | CHEK2ALDH1A1PKMADORA2AADORA2B | |
| SCHEMBL1378643 | 0.83 | CHEK2 (0.85) | CHEK2 | |
| SCHEMBL3559494 | 0.82 | CHEK2 (0.86) | CHEK2 | |
| SCHEMBL1380253 | 0.82 | CHEK2 (0.86) | CHEK2 | |
| SCHEMBL1379561 | 0.82 | CHEK2 (0.86) | CHEK2 | |
| SCHEMBL3571821 | 0.80 | CHEK2 (0.86) | CHEK2 | |
| SCHEMBL3919991 | 0.80 | CHEK2 (0.71) | CHEK2ALDH1A1KMT2APTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687639-B2 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-03-30 | — | — | US | disclosed |
| US-20060252793-A1 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | BW CONVERTING AB (SE) | 2006-11-09 | — | — | US | disclosed |
| US-7132440-B2 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252793-A1 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | CDKN1A, DDB1, TMBIM6 | CHEK2 14/4885KDM4E 3815/4885ALDH1A1 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.